Pharming Group N.V annual net income
2019
2020
2021
2022
2023
2024
2025
Pharming Group N.V Net Income Growth & History (PHAR)
Pharming Group N.V's net income was $2.5M for fiscal 2025.
View full Pharming Group N.V company overviewPharming Group N.V annual net income history
| Fiscal year | Period ended | Net income | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $2.5M | $14.4M | — |
| 2024 | 2024-12-31 | −$11.8M | −$1.3M | — |
| 2023 | 2023-12-31 | −$10.5M | −$24.2M | — |
| 2022 | 2022-12-31 | $13.7M | −$2.3M | −14.52% |
| 2021 | 2021-12-31 | $16.0M | −$21.8M | −57.62% |
| 2020 | 2020-12-31 | $37.7M | −$2.8M | −6.93% |
| 2019 | 2019-12-31 | $40.6M | — | — |
Pharming Group N.V quarterly net income
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Net income | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $1.6M | −$3.1M | −65.10% |
| Q1 2026 | 2026-03-31 | −$5.2M | — | — |
| Q4 2025 | 2025-12-31 | $5.3M | — | — |
| Q3 2025 | 2025-09-30 | $7.5M | — | — |
| Q2 2025 | 2025-06-30 | $4.7M | — | — |
Pharming Group N.V net income trends
Over the last five fiscal years, Pharming Group N.V's net income decreased from $37.7M to $2.5M, a change of −$35.2M. The latest reported quarter, Q2 2026, shows $1.6M.
About the metric
What net income means
Net income is a company’s bottom-line profit or loss after operating costs, interest, taxes, and other reported income and expenses. It shows how much of a company’s revenue ultimately remained as earnings, or how large its loss was, during a fiscal period.
Calculation and source
SEC-reported net income
TickerStat standardizes consolidated net income or profit and loss reported in company SEC filings for aligned fiscal periods. It is not adjusted earnings, an analyst estimate, or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Pharming Group N.V source filings ↗Community posts
Pharming expands Joenja approval to younger children with APDS
Pharming ($PHAR) secured FDA approval to use Joenja in children aged four to 11 with activated PI3K delta syndrome who weigh at least 27 kilograms. The expansion adds younger patients to the medicine’s existing indication for older patients ...